Malaria is still one of the leading causes of death worldwide, with an estimated 247 million cases and 619,000 deaths reported in 2021. The main epidemic areas of malaria are distributed in Africa (96%), followed by Southeast Asia (SE Asia) (2%) and the Eastern Mediterranean Region (2%). The World Health Organization (WHO) hopes to eliminate malaria in at least 35 additional countries (based on data from 2021) by 2030. Quinine (Figure , 1) was the sole antimalarial drug used since its discovery in the 19 th century, followed by chloroquine (2). However, due to emerging chloroquine resistance, more antimalarial drugs such as amodiaquine (ADQ, 3) were discovered. Figure : The structures of current antimalarial agents; quinine (1), chloroquine (2), amodiaquine (3) and artesunate (4). ADQ (3), first discovered in 1948, is a 4-aminoquinoline antimalarial drug used (in base or acid form) as an alternative against chloroquine-resistant strains. Due to the severe side effects from the sole use of ADQ (3), the World Health Organisation (WHO) has recommended the implementation of artemisinin-based combination therapy (ACT), which is the pairing of ADQ (3) with artemisinin derivatives such as artesunate (4) as a first-line of treatment for uncomplicated malaria. A 2006 study on the use of ACT in a village in Uganda concluded that the use of ACT offered an important step forward for the treatment of malaria in Africa and that more extensive research into the development of a cost-effective ACT as well as coformulations is a necessity. Despite the available antimalarial drugs such as amodiaquine (3), most of sub-Saharan Africa still lacks adequate access to good quality, affordable antimalarial drugs due to most active pharmaceutical ingredients (APIs) being imported from other countries. While published processes are available for ADQ and 4,7-DCQ, each of these methods have limitations such as low yields, formation of impurities, the use of expensive solvents or hazardous solvents or more unit operations are required for production of Amodiaquine, which drives up the energy requirements. Additionally, no methods are reported for the removal of impurities or for the exact determination of the crystal water molecules in ADQ. These limitations make it difficult to produce ADQ (3) at a competitive price.